Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Non-ST-Elevation Myocardial Infarction

  • Kim Chang Hoon
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Lee Seung Hun
    Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School
  • Kim Hyun Kuk
    Department of Internal Medicine and Cardiovascular Center, Chosun University Hospital, University of Chosun College of Medicine
  • Kim Min Chul
    Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School
  • Kim Ju Han
    Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School
  • Hong Young Joon
    Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School
  • Ahn Young Keun
    Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School
  • Jeong Myung Ho
    Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School
  • Hur Seung Ho
    Keimyung University Dongsan Medical Center
  • Kim Doo Il
    Department of Cardiology, Inje University Haeundae Baek Hospital, Inje University College of Medicine
  • Chang Kiyuk
    Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
  • Park Hun Sik
    Department of Internal Medicine, Kyungpook National University Hospital
  • Bae Jang-Whan
    Department of Internal Medicine, College of Medicine, Chungbuk National University
  • Jeong Jin-Ok
    Chungnam National University Hospital, Chungnam National University College of Medicine
  • Park Yong Hwan
    Samsung Changwon Hospital, Sungkyunkwan University School of Medicine
  • Yun Kyeong Ho
    Wonkwang University Hospital
  • Yoon Chang-Hwan
    Seoul National University Bundang Hospital
  • Kim Yisik
    Chonbuk National University Hospital and Chonbuk National University Medical School
  • Hwang Jin-Yong
    Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine
  • Kim Hyo-Soo
    Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital
  • Choi Ki Hong
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Park Taek Kyu
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Yang Jeong Hoon
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Song Young Bin
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Hahn Joo-Yong
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Choi Seung-Hyuk
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Gwon Hyeon-Cheol
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Lee Joo Myung
    Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine

抄録

<p>Background: Limited data exist regarding the prognostic implications of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with non-ST-elevation myocardial infarction (NSTEMI) who undergo percutaneous coronary intervention (PCI).</p><p>Methods and Results: Of 13,104 patients in the nationwide Korea Acute Myocardial Infarction Registry-National Institutes of Health, 3,083 patients with NSTEMI who underwent PCI were included in the present study. The primary endpoint was major adverse cardiovascular events (MACE) at 3 years, a composite of all-cause death, recurrent myocardial infarction, unplanned repeat revascularization, and admission for heart failure. NT-proBNP was measured at the time of initial presentation for the management of NSTEMI, and patients were divided into a low (<700 pg/mL; n=1,813) and high (≥700 pg/mL; n=1,270) NT-proBNP group. The high NT-proBNP group had a significantly higher risk of MACE, driven primarily by a higher risk of cardiac death or admission for heart failure. These results were consistent after confounder adjustment by propensity score matching and inverse probability weighting analysis.</p><p>Conclusions: In patients with NSTEMI who underwent PCI, an initial elevated NT-proBNP concentration was associated with higher risk of MACE at 3 years, driven primarily by higher risks of cardiac death or admission for heart failure. These results suggest that the initial NT-proBNP concentration may have a clinically significant prognostic value in NSTEMI patients undergoing PCI.</p>

収録刊行物

  • Circulation Journal

    Circulation Journal advpub (0), 2024-04-11

    一般社団法人 日本循環器学会

参考文献 (25)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ